ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction

摘要

Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) which is FDAapproved for the treatment of patients with chronic heart failure with reduced ejection fraction (HFrEF).1) According to the 2016 American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America (ACC/AHA/HFSA) Focused Update on New Pharmacological Therapy for Heart Failure, ACEI, ARB, or ARNI are now recommended in patients with chronic symptomatic HFrEF to reduce morbidity and mortality (class I recommendation).